Somatostatin-analógok a pancreasrák kezelésében: utópia vagy egy lehetséges alternatíva?

Translated title of the contribution: Somatostatin analogs in the treatment of pancreatic cancer: utopia or feasible alternative?

A. Zalatnai, V. Pogány

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The authors give an overview on the clinical treatment results of pancreatic carcinoma with somatostatin analogs including octreotide, lanreotide and vapreotide. Numerous preclinical studies provided solid evidence that the growth of ductal pancreatic adenocarcinoma can successfully be inhibited using such synthetic analogs via direct (apoptosis-inducing) and various indirect mechanisms. In the clinical practice their role still remains contradictory. Monotherapy did not result in a prolongation of the survival, however, in 15-20% of patients the progression of the process has been halted for several months accompanied by a significant improvement of the clinical condition without notable side effects. Combination of octreotide with tamoxifen yielded a survival benefit in addition to the stabilization of the general condition, although reduction of the tumor mass has not been documented. Despite the modest results these finding reinforce the responsiveness of the pancreatic ductal cancer to the hormonal manipulations and further studies on optimization of the effects are of worth. While in the majority of cases the somatostatin receptors have been lost, hormonal control of the pancreatic cancer could be achieved by combination treatment modalities.

Original languageHungarian
Pages (from-to)2333-2338
Number of pages6
JournalOrvosi Hetilap
Volume141
Issue number43
Publication statusPublished - Oct 22 2000

Fingerprint

Utopias
Octreotide
Somatostatin
Pancreatic Neoplasms
Somatostatin Receptors
Survival
Tamoxifen
Adenocarcinoma
Apoptosis
Therapeutics
Growth
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Somatostatin-analógok a pancreasrák kezelésében : utópia vagy egy lehetséges alternatíva? / Zalatnai, A.; Pogány, V.

In: Orvosi Hetilap, Vol. 141, No. 43, 22.10.2000, p. 2333-2338.

Research output: Contribution to journalArticle

@article{099092ad59e84e12bb370f595e1a1a22,
title = "Somatostatin-anal{\'o}gok a pancreasr{\'a}k kezel{\'e}s{\'e}ben: ut{\'o}pia vagy egy lehets{\'e}ges alternat{\'i}va?",
abstract = "The authors give an overview on the clinical treatment results of pancreatic carcinoma with somatostatin analogs including octreotide, lanreotide and vapreotide. Numerous preclinical studies provided solid evidence that the growth of ductal pancreatic adenocarcinoma can successfully be inhibited using such synthetic analogs via direct (apoptosis-inducing) and various indirect mechanisms. In the clinical practice their role still remains contradictory. Monotherapy did not result in a prolongation of the survival, however, in 15-20{\%} of patients the progression of the process has been halted for several months accompanied by a significant improvement of the clinical condition without notable side effects. Combination of octreotide with tamoxifen yielded a survival benefit in addition to the stabilization of the general condition, although reduction of the tumor mass has not been documented. Despite the modest results these finding reinforce the responsiveness of the pancreatic ductal cancer to the hormonal manipulations and further studies on optimization of the effects are of worth. While in the majority of cases the somatostatin receptors have been lost, hormonal control of the pancreatic cancer could be achieved by combination treatment modalities.",
author = "A. Zalatnai and V. Pog{\'a}ny",
year = "2000",
month = "10",
day = "22",
language = "Hungarian",
volume = "141",
pages = "2333--2338",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "43",

}

TY - JOUR

T1 - Somatostatin-analógok a pancreasrák kezelésében

T2 - utópia vagy egy lehetséges alternatíva?

AU - Zalatnai, A.

AU - Pogány, V.

PY - 2000/10/22

Y1 - 2000/10/22

N2 - The authors give an overview on the clinical treatment results of pancreatic carcinoma with somatostatin analogs including octreotide, lanreotide and vapreotide. Numerous preclinical studies provided solid evidence that the growth of ductal pancreatic adenocarcinoma can successfully be inhibited using such synthetic analogs via direct (apoptosis-inducing) and various indirect mechanisms. In the clinical practice their role still remains contradictory. Monotherapy did not result in a prolongation of the survival, however, in 15-20% of patients the progression of the process has been halted for several months accompanied by a significant improvement of the clinical condition without notable side effects. Combination of octreotide with tamoxifen yielded a survival benefit in addition to the stabilization of the general condition, although reduction of the tumor mass has not been documented. Despite the modest results these finding reinforce the responsiveness of the pancreatic ductal cancer to the hormonal manipulations and further studies on optimization of the effects are of worth. While in the majority of cases the somatostatin receptors have been lost, hormonal control of the pancreatic cancer could be achieved by combination treatment modalities.

AB - The authors give an overview on the clinical treatment results of pancreatic carcinoma with somatostatin analogs including octreotide, lanreotide and vapreotide. Numerous preclinical studies provided solid evidence that the growth of ductal pancreatic adenocarcinoma can successfully be inhibited using such synthetic analogs via direct (apoptosis-inducing) and various indirect mechanisms. In the clinical practice their role still remains contradictory. Monotherapy did not result in a prolongation of the survival, however, in 15-20% of patients the progression of the process has been halted for several months accompanied by a significant improvement of the clinical condition without notable side effects. Combination of octreotide with tamoxifen yielded a survival benefit in addition to the stabilization of the general condition, although reduction of the tumor mass has not been documented. Despite the modest results these finding reinforce the responsiveness of the pancreatic ductal cancer to the hormonal manipulations and further studies on optimization of the effects are of worth. While in the majority of cases the somatostatin receptors have been lost, hormonal control of the pancreatic cancer could be achieved by combination treatment modalities.

UR - http://www.scopus.com/inward/record.url?scp=0034703605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034703605&partnerID=8YFLogxK

M3 - Article

C2 - 11089387

AN - SCOPUS:0034703605

VL - 141

SP - 2333

EP - 2338

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 43

ER -